# EDGAR Filing Document

**Accession Number:** 0001674930
**File Stem:** 0000950170-25-084869
**Filing Date:** 2025-6
**Character Count:** 9030
**Document Hash:** 14bf1576dd007957d16ffb418f3735f7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-084869.hdr.sgml**: 20250611

**ACCESSION NUMBER**: 0000950170-25-084869

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250609

**FILED AS OF DATE**: 20250611

**DATE AS OF CHANGE**: 20250611

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Hsieh Ming
- **CENTRAL INDEX KEY:** 0001302110

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37894
- **FILM NUMBER:** 251040461

**MAIL ADDRESS:**
- **STREET 1:** 4399 SANTA ANITA AVE.
- **CITY:** EL MONTE
- **STATE:** CA
- **ZIP:** 91731
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Ming Hsieh Trust
- **CENTRAL INDEX KEY:** 0001836339

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** CA

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37894
- **FILM NUMBER:** 251040460

**BUSINESS ADDRESS:**
- **STREET 1:** 4399 SANTA ANITA AVE.
- **CITY:** EL MONTE
- **STATE:** CA
- **ZIP:** 91731
- **BUSINESS PHONE:** 626-350-0537

**MAIL ADDRESS:**
- **STREET 1:** 4399 SANTA ANITA AVE.
- **CITY:** EL MONTE
- **STATE:** CA
- **ZIP:** 91731
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Fulgent Genetics, Inc.
- **CENTRAL INDEX KEY:** 0001674930
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 812621304
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 4399 SANTA ANITA AVE
- **CITY:** EL MONTE
- **STATE:** CA
- **ZIP:** 91731
- **BUSINESS PHONE:** 626-350-0537

**MAIL ADDRESS:**
- **STREET 1:** 4399 SANTA ANITA AVE
- **CITY:** EL MONTE
- **STATE:** CA
- **ZIP:** 91731

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Fulgent Diagnostics, Inc.
- **DATE OF NAME CHANGE:** 20160517

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Hsieh Ming<br><sub>(Last) (First) (Middle)</sub><br>C/O FULGENT GENETICS, INC.<br>4399 SANTA ANITA AVENUE<br><sub>(Street)</sub><br>EL MONTE, CA 91731<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-09 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Fulgent Genetics, Inc. [ FLGT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Ming Hsieh Trust<br><sub>(Last) (First) (Middle)</sub><br>C/O FULGENT GENETICS, INC.<br>4399 SANTA ANITA AVENUE<br><sub>(Street)</sub><br>EL MONTE, CA 91731<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-09 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Fulgent Genetics, Inc. [ FLGT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock |  |  |  |  |  |  |  | 810679 | D |  |
| Common Stock |  |  |  |  |  |  |  | 7895115 | I | By Trust<sup>(1)</sup> |
| Common Stock |  |  |  |  |  |  |  | 220816 | I | By Trust<sup>(2)</sup> |
| Common Stock |  |  |  |  |  |  |  | 1000 | I | Uniform Transfer to Minor Account<sup>(3)</sup> |
| Common Stock |  |  |  |  |  |  |  | 1000 | I | Uniform Transfer to Minor Account<sup>(3)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Forward sale contract (obligation to sell) | <sup>(4)(5)</sup> | 2025-06-09 |  | J<sup>(4)(5)</sup> |  |  | 800000<sup>(4)</sup> | <sup>(4)(5)</sup> | <sup>(4)(5)</sup> | Common Stock | 800000 | <sup>(4)(5)</sup> | 0 | I | By Trust<sup>(1)(4)(5)</sup> |

---

### Footnotes:

(1) Securities held by The Ming Hsieh Trust (the "Trust"). Mr. Hsieh is the trustee of the Trust and possesses the sole voting and dispositive power with respect to securities held by the Trust.

(2) Securities held by the Dynasty Trust. Mr. Hsieh is the grantor of the Dynasty Trust and he and his spouse, Eva Hsieh, and Jian Xie serve on the investment committee of the Dynasty Trust. Mr. Hsieh disclaims any beneficial interest except with respect to any pecuniary interest therein.

(3) Shares held in a Uniform Transfers to Minor Act account for which Ming Hsieh acts as custodian and possesses the sole voting and dispositive power.

(4) Previously, on September 14, 2022, the Trust entered into a prepaid variable forward agreement (the "2022 Agreement") with an unaffiliated bank (the "Bank"). The 2022 Agreement obligated the Trust to deliver up to 800,000 shares of the issuer's common stock, $0.0001 par value per share ("Common Stock") (or, at the Trust's election, an equivalent amount of cash) to settle the 2022 Agreement.

(5) On June 9, 2025, the Trust elected to cancel the 2022 Agreement with respect to all 800,000 shares. In connection with the cancellation, the Trust paid an aggregate of $16,446,960.00 to the Bank. Following the payment and cancellation described above, the 800,000 shares held by the reporting person that were previously subject to the prepaid forward contract are no longer pledged to the Bank.

**Signature:** /s/ Paul Kim as Attorney-in-Fact  
**Date:** 2025-06-11

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**